Esther Lu

Medicine & Life Sciences

1. Neoplasms 100%
2. Survival 91%
3. Cancer Survivors 75%
4. Weight Loss 60%
5. Pancreatic Neoplasms 59%
6. Adenocarcinoma 56%
7. Mortality 55%
8. Recurrence 55%
9. Pancreaticoduodenectomy 53%
10. 130-nm albumin-bound paclitaxel 49%
11. Health 46%
12. Randomized Controlled Trials 46%
13. Alzheimer Disease 44%
14. Radiotherapy 40%
15. Confidence Intervals 40%
16. Drug Therapy 40%
17. Breast Neoplasms 40%
18. Prostatic Neoplasms 39%
19. Lung 39%
20. Transplants 39%
21. Squamous Cell Carcinoma of Head and Neck 39%
22. Overweight 36%
23. Radiosurgery 35%
24. Diet 35%
25. Cetuximab 35%
26. Odds Ratio 35%
27. Progression-Free Survival 34%
28. Biomarkers 34%
29. Tissue Donors 33%
30. gemcitabine 33%
31. Costs and Cost Analysis 32%
32. Clinical Trials 32%
33. Therapeutics 31%
34. Health Insurance 31%
35. Non-Small Cell Lung Carcinoma 29%
36. Decision Support Techniques 28%
37. Lymphoma, Large B-Cell, Diffuse 27%
38. Quality of Life 26%
39. Lung Neoplasms 26%
40. Four-Dimensional Computed Tomography 26%
41. Allogeneic Cells 26%
42. Albumin-Bound Paclitaxel 26%
43. Neuroendocrine Tumors 25%
44. Endometrial Neoplasms 24%
45. Neoadjuvant Therapy 24%
46. Implementation Science 24%
47. Tomography 24%
48. Comorbidity 23%
49. Arnold-Chiari Malformation 23%
50. Sample Size 23%